Abstracts tagged "Infection"

Abstract Number: 1450 • 2015 ACR/ARHP Annual Meeting
Clostridium Difficile Infection-Associated Reactive Arthritis in a Pediatric Cohort
Daniel B. Horton^1,2,3, Brian L. Strom^1,3, Mary E. Putt³, Carlos D. Rose², David D. Sherry⁴ and Julia S. Sammons⁵, ¹Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE, ³Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Division of Pediatric Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pediatrics, Infection Prevention and Control, Division of Infectious Diseases, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The incidence of Clostridium difficile infection (CDI) has increased among children, and CDI is associated with significant morbidity and mortality. Cases of C. difficile…
Abstract Number: 1521 • 2015 ACR/ARHP Annual Meeting
Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic
Renata Baronaite Hansen¹, Anne Brun Hesselvig², Rolf Magnus Arpi², Eva Kristin Jonassen¹, Gunhild Bukh¹ and Ole Rintek Madsen¹, ¹Department of Rheumatology/C, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Department of Clinical Microbiology, Department of Clinical Microbiology, Copenhagen University Hospital Herlev, Herlev, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) treated with biologic agents are at increased risk of infection. Therefore, screening for urinary tract infection (UTI) with urine…
Abstract Number: 1692 • 2015 ACR/ARHP Annual Meeting
Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alice B. Gottlieb², Alan Menter³, Philip J. Mease⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, G James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor University Medical Center, Dallsa, TX, ⁴Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: To describe the rates of serious infections in psoriasis patients with psoriatic arthritis(PsA) from PSOLAR. Methods: PSOLAR is an international, disease-based, observational study in…
Abstract Number: 2032 • 2015 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis
Olga S. Zhukov¹, Rania W. Abolhosn¹, Jonnielyn G. Rivera¹, Mary Lape Nixon², Robert J. Lagier³, Harry E. Prince⁴, Hollis J. Batterman⁴ and Stanley J. Naides¹, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Lab Sciences, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Lab Services, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA
Background/Purpose: Chikungunya fever virus (CHIK) is emerging in the western hemisphere as a mosquito-borne, acute onset arthritis. The majority of cases progress to persistent moderate…
Abstract Number: 2034 • 2015 ACR/ARHP Annual Meeting
Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center
Barbara Goldstein¹, Jeffery J. Swigris², Shannon Kasperbauer¹, Pearlanne Zelarney¹ and JoAnn Zell¹, ¹Medicine, National Jewish Health, Denver, CO, ²National Jewish Health, Denver, CO
Background/Purpose: National Jewish Health (NJH) is a tertiary referral center for pulmonary and immunologic disease. The infectious disease division at NJH specializes in the care…
Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 2251 • 2015 ACR/ARHP Annual Meeting
Current Tobacco Use and the Rates of Postoperative Complications after Total Knee Arthroplasty
Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To our knowledge, well-designed studies that have examined the risk of post-arthroplasty implant-related complications after TKA with tobacco use are lacking. Our objective was…
Abstract Number: 2799 • 2015 ACR/ARHP Annual Meeting
Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE
Eliza F. Chakarvarty¹, Jacy Odell², Astrid Rasmussen³, Kathy L. Sivils², Joel M. Guthridge² and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Increasing data has suggested that individuals with systemic lupus (SLE) are at increased risk of herpes zoster (HZ) reactivation compared to healthy controls and…
Abstract Number: 49 • 2015 ACR/ARHP Annual Meeting
Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld² and Mona Trivedi³, ¹Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Rheumatology, Amgen, Thousand Oaks, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for serious hospitalized infectious events (HIEs). Research suggests that tumor necrosis factor alpha inhibitors…
Abstract Number: 2817 • 2015 ACR/ARHP Annual Meeting
The Microbiome of Reactive Arthritis in a Guatemalan Cohort
Alexis Ogdie-Beatty¹, Carles Ubeda², Helga Raquel Garcia Ferrer³, Joan Von Feldt⁴, A Garcia Kutzbach⁵ and Jose U. Scher⁶, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Institute for Research in Public Health, Valencia, Spain, ³Society for Worldwide Med Exchange, North Bay Village, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Internal Medicine, Rheumatology Unit (AGAR), Francisco Marroquin University, School of Medicine, Guatemala City, Guatemala, ⁶Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Reactive arthritis (ReA) is an inflammatory arthritis that typically follows infection. Several agents microbial agents have been implicated, particularly Shigella, Salmonella, Campylobacter in the…
Abstract Number: 2155 • 2014 ACR/ARHP Annual Meeting
Chikungunya Fever in Patients Under Biologics
Lauren Brunier¹, Katleen Polomat², Christophe Deligny², Veronique Dehlinger³, Patrick Numeric⁴, Georges Jean-Baptiste³, Serge Arfi² and Michel De Bandt⁵, ¹CHUM de Martinique,, Unit of rheumatology, CHUM, 97200 Fort de France, France, ²CHUM de Martinique,, unit of internal medicine, Fort de France, France, ³CHUM de Martinique,, Unit of rheumatology, CHUM, Fort de France, France, ⁴route de Chateauboeuf, 97200; French West Indies, Unit of rheumatology, CHUM, Fort de France, France, ⁵Rheumatology, Hopital Zobda-Quitman. CHU La Meynard., Fort de FRance, France
Background/Purpose Chick is an epidemic disease due to an arthropod-borne virus (Alphavirus) transmitted by Aedes mosquitoes. CHIKV causes an acute illness with a febrile phase,…
Abstract Number: 2128 • 2014 ACR/ARHP Annual Meeting
Effectiveness of ¹⁸f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia-like Illness
Hideyuki Horikoshi¹, Takashi Nakanishi¹, Reiko Takahashi¹, Fumihiko Kimura² and Kenji Itoh¹, ¹Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, ²National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that affects the elderly. It is characterized by pain and stiffness in the shoulder and pelvic girdles. …
Abstract Number: 1435 • 2014 ACR/ARHP Annual Meeting
Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan.
Yoichiro Akiyama¹, Takeo Sato¹, Takamasa Murosaki¹, Katsuya Nagatani¹ and Seiji Minota², ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi-Ken, Japan
[Background/Purpose ] Infliximab was introduced in 2002 as the first biological DMARD (bDMARD) in Japan. Currently, 5 TNF inhibitors, tocilizumab, and abatacept are available. Tacrolimus…
Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Treating Pediatric Rheumatologic Disease
Arunima Agarwal¹, Anusha Ramanathan² and Rhina Castillo³, ¹Pediatric Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Pediatric Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA
Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].